A Phase 1 interventional study of SHR7280 Tablet and SHR7280 Placebo Tablet in Endometriosis, Uterine Fibroids and Assisted Reproduction, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Endometriosis with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Endometriosis · China.
Among the 47 studies in Endometriosis with a site in China, this one is the 26th largest by enrollment of the 28 interventional ones that give a count, is one of 8 that started in 2025, is one of 5 in phase 1, and was the 36th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →16 of the 47 studies in Endometriosis with a site in China are open now. Recruiting first, the newest first:
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–45 · Women only
Catherin Zhang · Sites in China
Ages 18–75 · Women only
Obstetrics & Gynecology Hospital of Fudan University · Sites in China
Ages 18–55 · Women only
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18–50 · Women only
Li Li · Sites in China
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 6 · Phase 4 3
First in 2008; this study’s year is marked. 8 started in 2025.
This study's enrollment of 16 is below the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 161 across the 28 interventional studies, 402 across the 19 observational. Of the 16 that completed or were terminated, 3 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 47 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Jiangsu HengRui Medicine Co., Ltd. has 4 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Endometriosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
| NCT06266897Zhujiang HospitalA Study on the Correlation Between Endometriosis and Intra-tissue Microbiota | 2026-12 |
| NCT07014761Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe Influence of Central Sensitization in Endometriosis Disease | 2027-03-31 |
| NCT07755956Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis | 2027-03-31 |
| NCT06584760The Fourth Affiliated Hospital of Zhejiang University School of MedicineResearch on the Impact of Chronic Pelvic Pain on Endometriosis | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 47 studies in Endometriosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the effect of high-fat meal on pharmacokinetics of SHR7280 after oral administration and the effect of SHR7280 on QT interval at low and high doses in healthy Chinese volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR7280 Tablet · Drug: SHR7280 Placebo Tablet
Drug: SHR7280 Tablet · Drug: SHR7280 Placebo Tablet
Oral SHR7280 tablet.
Oral SHR7280 placebo tablet.
Peak concentration (Cmax)
Time frame: Day 1 to Day 8.
Area under the plasma concentration-time curve from time 0 to the last quantifiable timepoint (AUC0-t)
Time frame: Day 1 to Day 8.
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)
Time frame: Day 1 to Day 8.
Time to peak concentration (Tmax)
Time frame: Day 1 to Day 8.
Elimination half-life (t1/2)
Time frame: Day 1 to Day 8.
Adverse events (AEs)
Time frame: Day 1 to Day 15.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Jul 2025, 1 month.
Of 24 phase 1 interventional studies under Endometriosis, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 26. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GnRH Antagonist SHR7280
Jiangsu HengRui Medicine Co., Ltd. →